Axovant Sciences Ltd.
Clarendon House
2 Church Street
Hamilton
HM 11
Website: http://www.axovant.com/
Email: info@axovant.com
96 articles with Axovant Sciences Ltd.
-
Axovant to Host First R&D Day on March 29
3/27/2019
Axovant’s chief executive officer, Pavan Cheruvu, MD, will provide opening remarks and Gavin Corcoran, MD, executive vice president of R&D, will moderate the event.
-
Axovant Announces Clinical Update from First Tay-Sachs Disease Patient Dosed with AXO-AAV-GM2 Gene Therapy
3/11/2019
Generally well-tolerated with no serious adverse events in a 30-month-old patient with advanced infantile Tay-Sachs disease
-
Axovant Releases Positive Interim Updates for Parkinson's and Tay-Sachs Gene Therapy Trials
3/11/2019
Axovant has been busy, releasing interim results from two different clinical trials, one for Tay-Sachs, the other for Parkinson’s disease. -
Axovant to Host First R&D Day March 29, 2019
2/21/2019
Axovant Sciences (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that it will host its first R&D Day for investors and analysts in New York City on Friday, March 29, 2019, beginning at 8:30 a.m. ET.
-
Axovant Sciences, one of Vivek Ramaswamy’s biotech companies under the Roivant Sciences’ umbrella, is forming a company called Arvelle Therapeutics. Arvelle is a strategic transition of Axovant’s legacy small molecule team.Biopharmaceuticals
-
Axovant Announces Formation of Arvelle Therapeutics and Strategic Transition of Legacy Small Molecule Team into Newly Formed Company
2/14/2019
Axovant Sciences (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announces the formation of Arvelle Therapeutics and the strategic transition of its legacy small molecule team into the newly-formed company.
-
Biotech entrepreneur Vivek Ramaswamy has launched another subsidiary for Roivant Sciences. Ramaswamy will provide an update on the new company, as well as other members of the Roivant family during a Monday presentation at JPM19.
-
Days after Axovant announced an end to focusing on its legacy small molecule portfolio in favor of gene therapies, the company announced it has licensed worldwide rights to two gene therapy programs from the University of Massachusetts School of Medicine.
-
Axovant Licenses Investigational Gene Therapies for GM1 Gangliosidosis, Tay-Sachs and Sandhoff Diseases from University of Massachusetts Medical School
12/13/2018
Axovant Sciences, announced that it has licensed exclusive worldwide rights for the development and commercialization of two novel gene therapy programs to address GM1 gangliosidosis and GM2 gangliosidosis from the University of Massachusetts (UMass) Medical School.
-
There is very little doubt that developing drugs for neuroscience disorders in general and dementias in particular is a high-risk business. Axovant Sciences, unfortunately, seems to be finding that out the hard way.
-
Axovant Announces Feedback From FDA Meeting Regarding AXO-Lenti-PD for Parkinson's Disease and Progress in Ongoing SUNRISE-PD Phase 2 Clinical Trial
12/6/2018
Meeting with FDA confirmed that studies previously conducted using first generation ProSavin® may be considered part of a single development program with AXO-Lenti-PD
-
Yposkesi enters into agreement in principle for strategic partnership with Axovant to expand Axovant’s gene therapy manufacturing capacity
11/28/2018
In the framework of a preferred partnership, Yposkesi plans to grant Axovant access to dedicated cGMP capacity and manufacturing resources to further support the global development and commercialization of Axovant’s AAV-based gene therapy programs
-
Toward the end of every year, biopharma executives are asked to dust off their crystal balls and predict what the next year might reveal. It’s that time of year again! Find out what execs are saying about M&A, gene therapy, sickle cell, and more.
-
BioSpace Movers and Shakers: Nov. 26
11/26/2018
In a short week leading up to Thanksgiving, several companies made leadership changes as they eye the coming year. We round up who made power moves this past week. -
Axovant Strengthens Team with Additional Expertise to Support Gene Therapy Pipeline
11/26/2018
Axovant Sciences (NASDAQ: AXON), a company developing innovative gene therapies for neurological and neuromuscular diseases, today announced the addition of five senior team members to strengthen its expertise in the development and commercialization of gene therapies.
-
Vivek Ramaswamy’s Roivant Sciences, the umbrella company to 14 Vant companies, including Datavant, Enzyvant Sciences, Urovant Sciences and others, raised another $200 million in equity financing.
-
Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD, A Novel Gene Therapy for Patients with Parkinson’s Disease
10/25/2018
Initial data from the first cohort expected in first half of 2019
-
Incidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found. The U.S. Centers for Disease Control and Prevention published a new report in the journal Alzheimer’s & Dementia projecting the disease’s likely expansion, and for the firs...
-
Urovant Sciences, a Vivek Ramaswamy company under the Roivant umbrella, has filed for an initial public offering (IPO) to raise $150 million. It will list on Nasdaq under the UROV symbol.
-
Kymriah® (tisagenlecleucel, formerly CTL019) receives European Commission Approval
8/28/2018
Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes that the European Commission (EC) has approved the Novartis CAR-T cell therapy, Kymriah® (tisagenlecleucel, formerly CTL019).